Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy
Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy
复制标题
DOI：
10.1002/ppul.10185
复制
发表时间：
2002-11-01
影响因子：
3.1
通讯作者：
Bitzan, MM
中科院分区：
文献类型：
--
作者：
Hoffmann, IM;Rubin, BK;Bitzan, MM
我们描述一位20岁的囊性纤维化患者，吸入妥布霉素后发生急性非少尿性肾衰竭。临床评价和肾活检结果与氨基糖苷类诱导的变化一致。以前没有报告过吸入性氨基糖苷类引起的肾衰竭。然而，随着这种治疗方式的使用增加，发病率可能会上升。在报告的患者中，常规剂量吸入治疗导致的可测量妥布霉素水平表明药物可被全身吸收，可能发生肾小管毒性。(C)2002 Wiley-Liss，Inc.
We describe a 20-year-old patient with cystic fibrosis who developed acute nonoliguric renal failure associated with inhaled tobramycin. Clinical evaluation and renal biopsy findings were consistent with aminoglycoside-induced changes. Renal failure due to inhaled aminoglycosides has not been previously reported. The incidence may rise, however, with the increased use of this treatment modality. Measurable tobramycin levels due to inhalational therapy with conventional dosing in the reported patient indicate that the drug can be systemically absorbed, and renal tubular toxicity may occur. (C) 2002 Wiley-Liss,Inc.